A discussion of the new controversial ACC/AHA guideline updates, which reduced the level of evidence for CABG as a treatment for CAD patients with 3-vessel disease and normal LV function.  The panel provides a rebuttal on the benefits of CABG vs medical therapy and the reduction in class designation for CABG, as well as the use of the ISCHEMIA and other similar trials for drawing such comparative evidence conclusions.